We are a leading healthcare campus encompassing all fields of health: from healthcare and research to teaching and management.
Professionalism, commitment and research by professionals on the Campus are the key elements in offering patients excellent care.
We are committed to research as a tool to provide solutions to the daily challenges we face in the field of medical healthcare.
We generate, transform and transmit knowledge in all areas of the health sciences, helping to train the professionals of the future.
We are defined by our vocation for communication. We invite you to share everything that happens at Vall d'Hebron Barcelona Hospital Campus, and our doors are always open.
The clinical trials are indicated for patients with severe and moderate respiratory diseases and they are coordinated by Dr Benito Almirante and Dr Ricard Ferrer.
Vall d'Hebron Barcelona Hospital Campus together with four Spanish hospitals are joining two clinical trials to treat coronavirus cases with Remdesivir, a drug used during the Ebola outbreak in 2014.
Both clinical trials are indicated for patients with severe and moderate respiratory illness. The promoter of the trials is the pharmaceutical company Gilead, which is specialized in antiviral drugs for HIV, hepatitis B and C and influenza. On one hand, patients with moderate respiratory symptoms, diagnosed with Acute Respiratory Distress Syndrome (ARDS) will be studied and supervised under the coordination of Dr. Benito Almirante, Head of the Infectious Diseases Service of the Vall d'Hebron Barcelona Hospital Campus and head of the Infectious Diseases Research group of the Vall d'Hebron Research Institute (VHIR). On the other hand, patients with severe involvement will be studied and supervised by Dr. Ricard Ferrer, head of the Vall d'Hebron Intensive Care Service and head of the Shock, Organic Dysfunction and Resuscitation (SODIR) research group at VHIR.
As indicated by the Minister of Health, Salvador Illa, the analysis processes could take some weeks and obtain a result within a couple of months.
The involved hospitals are: Hospital Clínic de Barcelona, Hospital de Cruces de Bilbao and La Paz de Madrid. The Vall d'Hebron Barcelona Hospital Campus and the hospitals of Alcalà de Henares, Ramón y Cajal and 12 de Octubre of Madrid, as well as Carlos Haya of Málaga are incorporated immediately to the project.
Remdesivir is an antiviral drug that acts inhibiting replication of infected cells and thus preventing the virus from multiplying and spreading. It was developed as a treatment for Ebola virus and infections caused by the Marburg virus. It was later discovered to exhibit reasonable antiviral activity against other viruses, including the respiratory syncytial virus, the Junín virus, the Lassa fever virus, and possibly the coronavirus that causes MERS (Middle East Respiratory Syndrome), the MERS-CoV.
The Minister of Health also explained that the Spanish Medicine Agency has authorized another trial promoted by the AIDS Foundation to treat confirmed non-serious cases. This treatment could be effective as a prevention strategy for people who have been close to confirmed positive patients. Similarly, Illa announced that the World Health Organization (WHO) is also collaborating and preparing a prevention trial for health professionals.
Intensive Care Medicine,
Select the newsletter you want to receive:
By accepting these conditions, you are agreeing to the processing of your personal data for the provision of the services requested through this portal, and, if necessary, for any procedures required by the administrations or public bodies involved in this processing, and their subsequent inclusion in the aforementioned automated file. You may exercise your rights to access, rectification, cancellation or opposition by writing to firstname.lastname@example.org, clearly stating the subject as "Exercising of Data Protection Rights".
Operated by: Vall d’Hebron University Hospital Foundation – Research Institute.
Purpose: Manage the user’s contact information.
Rights: To access, rectify, and delete personal information data, as well to the portability thereof and to limit and/or oppose their use.
Source: The interested party themselves.